Actionable molecular testing
for metastatic CRC.
A guideline-complete biomarker panel — RAS · BRAF · MSI · HER2 and beyond — designed to guide first-line therapy in metastatic colorectal cancer. Built on the same fast, ultra-sensitive PCR platform that powers PulmoSmart and LiquiSmart Lung.
Why colorectal is next.
Colorectal cancer is one of the fastest-growing cancer diagnoses in India — and one of the most under-tested. The molecular subtype dictates first-line therapy, but a large fraction of patients start treatment without ever being profiled.
ONCO X is bringing the same speed, sensitivity and lab-friendly economics that made PulmoSmart possible — to the CRC clinic.
What it will cover.
- RAS (KRAS, NRAS) — hotspot mutations
- BRAF V600E
- MSI / MMR status
- HER2 amplification
- PIK3CA hotspots
- NTRK fusions
- Additional markers finalising in clinical validation
Be the first to know when it launches.
Register your interest and we'll get in touch when the CRC panel is ready for early-access sites and clinical validation partners.
Register interest